Kornimate/medical-research-clean huggingface dataset:
iraps (secreted insulin regulated aminopeptidase): a new insulin sensitivity biomarker

Conditions: Insulin Resistance

Summary: previous studies have demonstrated defects in the trafficking and translocation of glut4 glucose transporter in skeletal muscle and adipose tissue to be a major cause of insulin resistance in humans. irap (secreted insulin regulated aminopeptidase) is a protein which collocalizes and is translocated with glut4 to the plasma membrane in response to insulin. the extracellular domain of irap is cleaved and released in the bloodstream. therefore, irap plasma concentration could be a good marker of insulin sensitivity. in this study the investigators seek to confirm this hypothesis by using the gold standard of insulin sensitivity assessment: the hyperinsulinemic-euglycemic clamp. it is a multicenter descriptive study.


Eligibility criteria:
inclusion criteria: * men and women (sex ratio = 1) * aged from 18 to 35 years * fasting glycemia \< 6mmol/l * total cholesterol \< 7mmol/l * triglycerides \< 1.5 mmol/l * crpus \< 5 mg/l * creatinine clearance \< 80ml/min according to cockroft formula * liver enzymes (alanine aminotransférase and aspartate aminotransférase) \< 1.5 times normal values exclusion criteria: * subject not in compliance with the recommendations of french national law in force * medical history of metabolic disease (diabetes, dyslipidemia), endocrine disease, renal insufficiency * drug use that could affect glucose metabolism and the renin angiotensin aldosterone system * blood pressure \> 140/90mmhg * tea and coffee consumption more than 5 cups per day * subject who smoke more than 5 cigarettes per day

Keywords: irap insulin sensitivity marker
the effects of mass media photographs on drug-related stigma

Conditions: Opioid Use Disorder; Substance Use Disorders; Stigma, Social

Summary: the aim of this study was to evaluate the effects of exposure to drug-related photos used by the media on emotions, stigma towards people who use drugs, and public health services for this population.

this randomized experiment evaluated the impact of drug-related photographs used by the media on stigma towards people who use drugs. a nationally representative sample of us adults was randomized to view different photos used in the media (a person injecting drugs, a person being resuscitated after an overdose, a person receiving treatment, a person in recovery, or a person who had lost a family member to an overdose) and then asked questions about their feelings towards people who use drugs and their acceptance of public health services to address the overdose crisis.

Eligibility criteria:
inclusion criteria: * participant in existing web-based survey panel (norc's amerispeak) exclusion criteria: * not able to complete experiment and survey in english
spanish version of the kbild questionnaire

Conditions: Pulmonary Fibrosis

Summary: the purpose of the present study is to advance in the knowledge of quality of life in patients with ild by translating a ild quality of life questionnaire. there are no specific tools validated in spanish to evaluate the quality of life in patients with ild, although these measures are useful for an comprensive evaluation of these patients. patients with ild have a significant impact on their health. if we improve our knowledge of the different domains affected by the disease, and not only in the pathophysiological ones, we will be able to develop tools to improve their management.


Eligibility criteria:
inclusion criteria 1. subjects older than 18 years. 2. diagnosis of ild, established according to the consensus documents of the ats and ers \[1,2\]. 3. acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits. exclusion criteria 1. another chronic respiratory disease other than epid. 2. psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).
role of vitamin e in gaucher disease patients

Conditions: Gaucher Disease

Summary: gaucher disease (gd) can be classified into three clinical types .type 1,the most common type ,is the chronic non neuronpathic form of the disease,which shows gighly variable signs and symptoms and variable course,with visceral,skeletal and hematologic involvement among others.the neurologocal involvement can be observed in types 2 and 3

enzymatic defeciency in gaucher disease patients may induce a cascade of events that result in side effects, such as the production of reactive oxygen species(ros) and reactive nitrogen species(rns) that can then generate the oxidative stress whereas in body of healthy individuals,the production and degradation of ros and rns are generally balanced. neurochemical abnormalities in patients with gaucher disease might be related to oxidative stress and inflammation in the brain. oxidative stress induces peroxiredoxin-2 as cytoprotective response against rns .it is able to detoxify a vast range of organic peroxides. vitamin e well accepted nature most effective lipid soluble chain breaking antioxidant .

Eligibility criteria:
inclusion criteria: children and adolescents aged fron 2 to 18 years old with gaucher disease both type 1 and type 3 diagnosed clinically and confirmed by laboratory analysis patients who are on stable enzyme replacement therapy for at least 6 months - exclusion criteria: patients with infection or another inflammatory condition patients on multivitamin therapy known chronic liver disease (viral hepatitis,hiv) patients with renal impairement defined as creatinine level greater 1.2 for female and greater than 1.4 for male. -
sympathetic transduction in obesity-associated hypertension (ob-htn)

Conditions: Hypertension; Obesity

Summary: the purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. the study will also investigate how hypertension and obesity influence the nervous system and vascular function. the study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.


Eligibility criteria:
inclusion criteria: * control - bmi\<30, age 18-55 * hypertensive - bmi\ 30, age 18-55 obese-hypertensive- bmi\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring exclusion criteria: all groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Keywords: npy
efficacy and safety study to delay renal failure in children with alport syndrome

Conditions: Renal Insufficiency, Chronic

Summary: this is a phase iii, multi-centre, randomised, placebo-controlled, patient and investigator-blind study in paediatric patients with early stages of alport syndrome to assess the safety and efficacy of the acei ramipril in slowing disease progression. alport syndrome stages that describe the extent of renal damage and loss of function are defined as: * 0 microhaematuria without microalbuminuria (usually at birth) * i microalbuminuria (30-300 mg albumin/gcrea) * ii proteinuria \>300 mg albumin/gcrea * iii \> 25% decline of normal renal function (creatinine clearance) * iv end stage renal failure (esrf) eligible patients with alport stages 0 and i will be randomly assigned at a 2:1 ratio to receive once daily ramipril or placebo. in addition, alport stage ii patients may be treated open label. eligible patients who, or whose parents/legal guardian refuse randomisation after eligibility is confirmed, and patients who have been treated with ramipril prior to the study, may be treated open-label with ramipril as per protocol. the total number of patients will not exceed 120, with the number of randomised patients not exceeding 60, and the number of patients treated open label from day 1 of the study aimed to be approximately 60. randomised patients whose disease progresses to the next disease level during the 3 year treatment period will be unblinded, and open label ramipril treatment will be initiated and continued, respectively, depending on prior treatment randomisation.


Eligibility criteria:
inclusion criteria: * definitive diagnosis of alport syndrome: kidney biopsy (patient or affected relative/s), and/or mutation analysis (hemizygous x-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss) * alport syndrome levels 0, i or ii at screening (microhaematuria without microalbuminuria or microalbuminuria \[30-300 mg albumin/gcrea\]) or proteinuria \>300 mg albumin/gcrea with gfr\>80ml/min). patients with alport stage ii are not subject to randomization but are treated opel label. * aged between ≥24 months and \<18 years at screening * assent from patient and informed consent from parents/legal guardian exclusion criteria: * uncertain diagnosis or variants of alport syndrome such as a heterozygous carrier * alport syndrome levels iii, or iv (albuminuria \>300 mg/g crea, creatinine clearance \<60 ml/min, or end stage renal failure \[esrf\]) * known allergies or intolerances to ramipril or related compounds * known contraindication for acei-therapy * additional chronic renal, pulmonary or cardiac diseases * pregnancy and lactation

Keywords: alport syndrome chronic kidney disease renal fibrosis nephroprotection pediatric study
educational intervention to adopt slt as first-line glaucoma treatment

Conditions: Primary Open-angle Glaucoma

Summary: the purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.

glaucoma is a disease characterized by optic nerve damage, visual field defects, elevated intraocular pressure (iop) and progressive vision loss. more than 3 million americans have glaucoma and more than 150,000 are blind as a result. regular use of glaucoma medications can usually lower intraocular pressure (iop), prevent disease progression, preserve vision and prevent blindness. however, many people with glaucoma do not always use their medication as directed, with about one-third to one-half of patients with glaucoma not taking their drops as often as necessary, or have difficulty putting in the drops. there are also numerous local side effects from using glaucoma eye drops including red eyes, blurry vision and dry eye symptoms. systemic side effects from eye drops range from triggering asthma, to lethargy and depression. selective laser trabeculoplasty (slt) has been used safely and effectively for the treatment of elevated iop in patients with open angle glaucoma for more than 20 years. slt may result in mild and temporary iop elevation, but this is a small risk and rarely significant. other side effects include blurred vison and inflammation of the cornea (front, clear part of the eye), but they are extremely rare. the purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be considered as first glaucoma treatment before the use of glaucoma eye drops.

Eligibility criteria:
inclusion criteria: * patients between 40 and 90 years of age * high-risk ocular hypertension, primary open-angle glaucoma, or pseudo-exfoliation glaucoma * currently treated with at least one glaucoma eye drop with stable intraocular pressure exclusion criteria: * previous laser trabeculoplasty * previous glaucoma surgery

Keywords: educational intervention slt selective laser trabeculoplasty poag eye drops primary open angle glaucoma
genetic and demographic factors that influence the pain and progress of labor

Conditions: Rapid Progress of Labor

Summary: the purpose of this study is to try to understand why the experience of labor differs among women. the investigators want to understand why some women have longer or shorter labors and why the amount of pain women experience is different. the investigators hope to be able to consider women more individually in terms of their pain and progress of labor.

there is enormous variability among women in the progress of normal labor. labor requires complex integrated interplay between the decidua, uterine cervix and myometrium that can take minutes, days or weeks to occur and is incompletely understood. understanding the biological variables that underlie differences in labor progress has been hampered by the lack of appropriate models that allow sensitive statistical analysis. identification of genetic and physiognomic factors that impact normal labor progress will allow for individualization of labor management and better use of societal resources. structural models of labor progress were first proposed by friedman in the 1950s at columbia university. aspects of friedman's model, such as the deceleration phase, have been debated since that time but friedman's model allowed for identification and quantification of the latent and active phase of labor in populations. these concepts have been modified by the world health organization as the who partogram, the use of which has resulted in reduced requirement of oxytocin and reduced incidence of cesarean section. dr. flood's group has developed a continuous bi-exponential model of labor progress and sigmoidal model for labor pain that the investigators have statistically and experimentally validated in several independent databases. the investigators model can be used both prospectively in an individual labor and with large cohorts to identify variables that significantly affect the progress of labor. the investigators have found in a previous work that parturients who carry g at the 27th amino acid beta-2 adrenergic receptors (β2ar) developed labor pain more rapidly that parturients with the common allele \[1\]. and the investigators also have found that catechol-o-methyltransferase (comt) rs4633 genotype tt resulted in a slower latent phase rate, and oxytocin receptor rs53576 genotype gg transitioned to active labor earlier \[2\]. in this new project, the investigators are planning to use bigger data base, to detect further genes associations, and tested some pharmacogenetic variations that could explain the different response to same medications and doses among patients.

Eligibility criteria:
inclusion criteria: * study participants will be women presenting in term labor. * patients of all ethnicities will be included. * all subjects will be greater than or equal to 18 years of age and able to give consent. exclusion criteria: * include preexisting pain syndromes or the regular taking of pain medications. * preterm birth (\< 37 weeks) and preeclampsia. * cervical dilatation more than 6 cm

Keywords: labor pain and progress, variation, genetic
evaluation of ecography as a diagnostic tool in the carpal tunnel syndrome compared to the studies of electroconduction

Conditions: Carpal Tunnel Syndrome

Summary: the main objective is to investigate the value of ultrasound in the diagnosis of carpal tunnel syndrome (cts), and among the secondary objectives, to establish the ultrasound parameters that are predictors of cts in comparison with neurophysiological studies, attempting to standardize a protocol and reference values that determine the presence or absence of cts. finally, cost-effectiveness analysis is proposed.

the reference test with which the ultrasound is compared is the neurophysiological test (npt). the expected timeline for the study is to be performed between july 2020 and may 2023.

Eligibility criteria:
inclusion criteria: 1. presenting clinical symptoms suggestive of cts, at least one of the following: * neuropathic profile pain in wrist-hand at the level of the median nerve territory (wrist, first-second-third, and radial half of the fourth finger by palmar and/or volar side), possibility of irradiation of the pain towards the forearm and/or arm. * nocturnal symptoms. * hypotrophy or atrophy of the thenar eminence. * self-described sensory alteration (sensation of cramping, numbness, tingling, hypoalgesia or analgesia). 2. age: 18 to 75 years. 3. consent to participate in the study. exclusion criteria: 1. previous surgery on the wrist 2. acquired or hereditary pathology causing peripheral neuropathies 3. polyneuropathy of any etiology 4. rheumatoid arthritis 5. diabetes mellitus

Keywords: carpal tunnel syndrome nerve conduction study ultrasound screening diagnosis
trial of prophylactic tamsulosin for postoperative urinary retention in primary total hip and knee arthroplasty patients

Conditions: Postoperative Urinary Retention

Summary: the study aims to evaluate the efficacy of prophylactic tamsulosin in reducing the incidence of postoperative urinary retention in primary total knee and hip arthroplasty patients.

prophylactic administration of tamsulosin will be compared to a placebo to evaluate the effectiveness in reducing the incidence of postoperative urinary retention in total hip and knee arthroplasty patients.

Eligibility criteria:
inclusion criteria: * men age 35 or older * primary total hip and knee arthroplasty patients (general, spinal, or epidural anesthesia * no current use (\>1 month) of alpha-blockers * community ambulator * adequate organ and marrow function as defined below: leucocytes at least 3,000/µl, absolute neutrophil count at least 1,500/µl, platelets at least 100,000/µl, creatinine within normal institutional limits * ability to understand, and the willingness to sign, a written informed consent exclusion criteria: * history of radical prostatectomy * receiving any other investigational agents * revision hip and knee arthroplasty patients * severe liver or kidney disease * taking strong inhibitors of cyp3a4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir, or conivaptan) * being on alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, phenoxybenzamine, or silodosin) * being of 5-alpha reductase inhibitors (finasteride, dutasteride) * history of allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, or phenoxybenzamine) * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * taking sildenafil,tadalafil, or vardenafil
safety and efficacy of tki258 in fgfr1 amplified and non-amplified metastatic her2 negative breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this trial is to determine the efficacy and safety profile of tki258 in 3 groups of patients with metastatic her2 negative breast cancer (bc) stratified by fgfr1 and hormone receptor (hr) status.


Eligibility criteria:
inclusion criteria: 1. female presenting with metastatic breast cancer. 2. tumor must have been tested by fish/cish for fgfr1 amplification. 3. her2 and hr status must have been determined. 4. patients must have her2 negative breast cancer. 5. patients must have a documented disease progression as define by recist at baseline. 6. patients with hr+ disease: * must have received at least one prior endocrine therapy in the metastatic setting. * must have received no more than three lines of chemotherapy in the metastatic setting. 7. patients with hr- disease must have received at least one and no more than three lines of chemotherapy in metastatic setting. exclusion criteria: 1. patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. 2. impaired cardiac function or clinically significant cardiac diseases, including any of the following: * history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation. * clinically significant resting bradycardia (\< 50 beats per minute). * lvef assessed by 2-d echocardiogram (echo) or multiple gated acquisition scanning (muga)\< 45%. 3. any of the following within 6 months prior to study entry: myocardial infarction (mi), severe/unstable angina, coronary artery bypass graft (cabg), congestive heart failure (chf), cerebrovascular accident (cva), transient ischemic attack (tia), pulmonary embolism (pe). 4. uncontrolled hypertension defined by a sbp \> 150mm hg and/or dbp \> 100mm hg, with or without anti-hypertensive medication. other protocol-defined inclusion/exclusion criteria may apply

Keywords: breast cancer her2 negative fgfr1
a phase ii optimization study of bms068645 and sestamibi planar imaging

Conditions: Cardiovascular Disease; Ischemic Heart Disease

Summary: the primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with technetium tc99m sestamibi following the administration of bms068645. the safety of bms068645 will also be studied.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * have known or suspected heart disease * have undergone a clinically indicated spect mpi study with adenosine in the last 24 hours to 14 days. * weigh between 88 and 250 lbs. exclusion criteria: * allergic reaction to technetium tc99m sestamibi or any of its components * history of asthma or lung disease * ingestion of caffeinated substances within 12 hours prior to the study
efficacy and safety study of naftopidil to patients treatment with luts

Conditions: Hyperplasia

Summary: the purpose of this study is to evaluate the effectiveness and safety of naftopidil and tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.

inclusion criteria: men ≥ 50 years signs and symptoms of bph a total ipss of ≥ 10 prostate volume of ≥20 ml (estimated by ultrasonography) pvr \> 150ml

Eligibility criteria:
inclusion criteria: * men ≥ 50 years * signs and symptoms of bph * ipss of ≥ 10 * prostate volume of ≥ 20 ml * pvr \> 150 ml exclusion criteria: * history of allergy to a ar antagonists * treatment with antiandrogen drugs * drugs with anticholinergic activity * significant history of orthostatic hypotension * concomitant neurological diseases * known or suspected neurogenic bladder dysfunction * carcinoma of the prostate or bladder * previous surgery for bph or bladder neck obstruction * history of recurrent uti * concomitant active uti

Keywords: naftopidil symptoms of lower urinary tract benign prostate hyperplasia luts